Source: Elsevier Global Medical News SAN FRANCISCO (EGMN) – Lymphedema is highly common and a source of considerable morbidity among patients who undergo treatment for head and neck cancer, finds a cross-sectional study among 103 survivors. Fully three-fourths had developed some degree of lymphedema, according to results presented at the annual Oncology Congress presented [...]
Continue reading...Monday, November 14, 2011
Source:MedScape.com Jethanamest D; Vila PM; Sikora AG; Morris LG Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, NY, USA. BACKGROUND: The head and neck is the most common site of mucosal melanoma, a cancer with poor prognosis. In contrast to cutaneous melanoma, mucosal melanoma of the head and neck (MMHN) is uncommon, with [...]
Continue reading...Friday, November 11, 2011
Source: The Wall Street Journal Author: Betsy McKay More than two-thirds of American smokers want to quit, but only a fraction actually do, underscoring a need for more services, messages, and access to medications to help them kick the habit, according to a new government report out today. Nearly 69% of adult smokers wanted to quit [...]
Continue reading...Wednesday, November 9, 2011
Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with [...]
Continue reading...Tuesday, November 8, 2011
Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and neck cancer. Data show that when combined with cisplatin-based chemotherapy, cetuximab improved overall survival, compared with chemotherapy alone. According to the researchers, this is [...]
Continue reading...Tuesday, November 1, 2011
Source: Jada.org An increase in the incidence and survival of oropharyngeal cancer in the United States since 1984 can be attributed to the human papilloma-virus (HPV) infection, say researchers in an article published online Oct. 3 in Journal of Clinical Oncology. The results of previous studies have shown that oropharyngeal cancers can be divided into [...]
Continue reading...Tuesday, October 25, 2011
Source: CNN.com A federal government advisory committee voted Tuesday to recommend that boys and young men, from ages 11 to 21, be vaccinated against the human papilloma virus, commonly referred to as HPV. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices says the vaccine series can be started as early as [...]
Continue reading...Tuesday, October 18, 2011
Source: Medscape News Today When head and neck cancer recurs and surgery is not an option, reirradiation provides the only potentially curative option. However, because the tumor often recurs in the same place or very close to tissue that has already been irradiated, this treatment approach represents a “significant challenge.” For this reason, it should [...]
Continue reading...Tuesday, October 18, 2011
The Asco Post D. Neil Hayes, MD, MPH, of the University of North Carolina at Chapel Hill, described efforts to position the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) in head and neck cancer treatment. Surprisingly negative results came from the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940), which showed [...]
Continue reading...Tuesday, October 4, 2011
Source: EurekAlert! Philadelphia — Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive from HPV16, according to a study published in Clinical Cancer Research, a journal of the American Association [...]
Continue reading...
Tuesday, December 6, 2011
0 Comments